EGFR and prostate cancer: For instance, along prostate cancer development, we previously identified that miR-133b represses the cell cycle control proteins RB1CC1 and PTPRK at the early androgen-dependent stage [4], thus essentially promotes cell proliferation; while another group identified miR-133b functions as tumor repressor by targeting epidermal growth factor receptor (EGFR) at the late androgen-independent stage [5].